慢性肝病临床显著门静脉高压的CT纳入与排除标准
本回顾性研究纳入235例慢性肝病患者,评估CT征象(脾大、胃食管静脉曲张、自发性门体分流、腹水)单独或联合诊断临床显著门静脉高压(HVPG≥10 mm Hg)的表现。联合脾大加至少一项其他征象作为纳入标准特异度94.4%-97.6%,任一征象作为排除标准敏感度94.5%-98.2%,72.8%-78.7%患者可正确分类。
要点
- 脾大联合至少一项其他CT征象(胃食管静脉曲张、自发性门体分流、腹水)诊断CSPH特异度达94.4%-97.6%。
- 任一征象(脾大、胃食管静脉曲张、自发性门体分流、腹水)存在诊断CSPH敏感度达94.5%-98.2%。
- 以联合征象为纳入标准、全部征象缺失为排除标准,72.8%-78.7%患者可正确分类,17.9%-23%无法分类。
核心结论
- CT上脾大、胃食管静脉曲张、自发性门体分流和/或腹水的存在或缺失,可能有助于纳入和排除慢性肝病患者的临床显著门静脉高压。
研究设计与样本
- 回顾性研究,纳入2001年1月至2019年12月两家三级机构中接受增强CT并在3个月内行肝静脉压力梯度测量的慢性肝病患者235例(平均年龄53.2岁±13.0,男性155例),由两名阅片者独立评估CT征象,以HVPG≥10 mm Hg为CSPH参考标准。
关键影像表现/征象
- CT上评估胃食管静脉曲张、自发性门体分流和腹水的存在。
- 脾大采用三种方法判定:基于深度学习算法测量的脾体积的个性化或固定体积标准,或手动测量的脾直径。
诊断标准与关键数值
- 脾大联合至少一项其他CT征象(胃食管静脉曲张、自发性门体分流、腹水)诊断CSPH特异度94.4%-97.6%。
- 任一征象(脾大、胃食管静脉曲张、自发性门体分流、腹水)存在诊断CSPH敏感度94.5%-98.2%。
- 以脾大联合至少一项其他征象为纳入标准、以脾大、胃食管静脉曲张、自发性门体分流和腹水均缺失为排除标准,235例中171-185例(72.8%-78.7%)正确分类,7-13例(3%-5.5%)错误分类,42-54例(17.9%-23%)无法分类。
- CSPH定义为HVPG≥10 mm Hg。
临床应用与阅片要点
- 阅片时可关注脾大、胃食管静脉曲张、自发性门体分流和腹水四项征象,用于CSPH的纳入或排除判断。
- 采用联合征象作为纳入标准时特异度高,采用任一征象作为排除标准时敏感度高,但部分患者(17.9%-23%)无法分类。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The value of CT in assessment of clinically significant portal hypertension (CSPH) has not been well determined. Purpose To evaluate the performance of CT features that have been associated with portal hypertension for diagnosing CSPH in patients with chronic liver disease (CLD). Materials and Methods This retrospective study included patients with CLD who underwent contrast-enhanced CT and subsequent hepatic venous pressure gradient (HVPG) measurement within 3 months at two tertiary institutions from January 2001 to December 2019. Two readers independently evaluated the presence of gastroesophageal varix, spontaneous portosystemic shunt (SPSS), and ascites on CT images. Splenomegaly at CT was determined using three methods, as follows: personalized or fixed volume criteria, based on spleen volume as measured by a deep learning algorithm, or manually measured spleen diameter. The diagnostic performance of these findings alone or in combination for detecting CSPH (HVPG ≥10 mm Hg) was evaluated. Results A total of 235 patients (mean age, 53.2 years ± 13.0 [SD]; 155 male patients), including 110 (46.8%) with CSPH, were included. Detection of CSPH according to the presence of both splenomegaly and at least one other CT feature (ie, gastroesophageal varix, SPSS, and ascites) achieved specificities of 94.4%-97.6%, whereas detection of CSPH according to the presence of any feature (ie, splenomegaly, gastroesophageal varix, SPSS, or ascites) achieved sensitivities of 94.5%-98.2%. When employing the former as rule-in criteria with the absence of splenomegaly, gastroesophageal varix, SPSS, and ascites as rule-out criteria for CSPH, 171-185 (range, 72.8%-78.7%) of 235 patients were correctly classified as either having CSPH or not, seven to 13 (range, 3%-5.5%) of 235 patients were incorrectly classified, and 42-54 (range, 17.9%-23%) of 235 patients were unclassified. Conclusion The presence or absence of splenomegaly, gastroesophageal varix, SPSS, and/or ascites on CT images may be useful for ruling in and ruling out CSPH in patients with CLD. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Fraum in this issue.
引用
- Heo S, Lee SS, Choi SH, et al. CT Rule-in and Rule-out Criteria for Clinically Significant Portal Hypertension in Chronic Liver Disease. Radiology. 2023. PMID: 37906011. doi:10.1148/radiol.231208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。